Literature DB >> 9728606

Automated cell count in flow cytometry: a valuable tool to assess CD4 absolute levels in peripheral blood.

M C Béné1, M N Kolopp Sarda, J El Kaissouni, A De March Kennel, C Molé, C Kohler, G C Faure.   

Abstract

The enumeration of lymphocyte subsets in absolute counts has long relied on different methods applied separately to whole blood cell count, lymphocyte differential appreciation, and flow cytometric evaluation of lymphocyte subsets percentages. The development of multicolor labeling methods inflow cytometry now allows a more homogeneous appreciation of several cell subsets among gated lymphocytes. The use of internal calibrators, such as microbead suspensions, also permits a direct appreciation of subsets in absolute counts in a single-platform method. These methods were compared with a traditional multiplatform method of assessing absolute counts of lymphocyte subsets in a pilot study in which all manipulations were performed by 1 person and in a full-scale larger study performed in the normal working conditions of a hospital laboratory. Microspheres seem to be a reliable tool to perform absolute count enumeration inflow cytometry, but several precautions in the sample preparation and flow cytometric analysis are required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728606     DOI: 10.1093/ajcp/110.3.321

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation Group.

Authors:  C T Schnizlein-Bick; J Spritzler; C L Wilkening; J K Nicholson; M R O'Gorman
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  ISHAGE-based single-platform flowcytometric analysis for measurement of absolute viable T cells in fresh or cryopreserved products: CD34/CD133 selected or CD3/CD19 depleted stem cells, DLI and purified CD56+CD3- NK cells.

Authors:  U Koehl; K Bochennek; R Esser; A Brinkmann; R Quaritsch; M Becker; J Soerensen; P Bader; D Schwabe; T Klingebiel; J Fischer; S Y Zimmermann
Journal:  Int J Hematol       Date:  2007-12-18       Impact factor: 2.490

Review 3.  The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia.

Authors:  Musa Yilmaz; Samantha Richard; Elias Jabbour
Journal:  Ther Adv Hematol       Date:  2015-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.